NeuroPace director granted shares and options

NeuroPace Inc director Lisa Andrade received new equity compensation consisting of common shares and stock options.

Rhea-AI Filing Summary

NeuroPace Inc director Lisa Andrade received new equity compensation consisting of common shares and stock options. She was granted 2,890 shares of Common Stock at no cost, all held directly. Following this grant, she directly owns 2,890 common shares.

She was also granted a Stock Option for 5,368 shares of Common Stock at an exercise price of $15.74 per share, expiring on June 4, 2036. Both the shares and the option vest in twelve equal monthly installments, contingent on her continuous service through each vesting date.

Insider Trade Summary

Grant/Award: 8,258 shares

Grant/Award 2 txns

Insider Andrade Lisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,368	$0.00	$0.00
Grant/Award	Common Stock	2,890	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,368 contracts (Direct); Common Stock — 2,890 shares (Direct)

Footnotes (2)

1. F1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
2. F2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Common Stock grant: 2,890 shares Shares held after grant: 2,890 shares Stock option grant size: 5,368 options +4 more

7 metrics

Common Stock grant 2,890 shares Equity award on June 5, 2026; held directly after grant

Shares held after grant 2,890 shares Total direct Common Stock holdings after non-derivative transaction

Stock option grant size 5,368 options Right to buy Common Stock granted June 5, 2026

Option exercise price $15.74 per share Conversion or exercise price for 5,368-share option

Option expiration June 4, 2036 Expiration date of Stock Option (Right to Buy)

Share vesting schedule 12 monthly installments Common Stock grant vests over twelve equal monthly tranches

Option vesting schedule 12 monthly installments Option shares vest and become exercisable monthly, subject to service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"She was also granted a Stock Option (Right to Buy) for 5,368 shares of Common Stock"

exercise price financial

"at an exercise price of $15.74 per share, expiring on June 4, 2036"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"vest in twelve equal monthly installments, contingent on her continuous service through each vesting date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeuroPace (NPCE) director Lisa Andrade acquire in this Form 4?

Lisa Andrade received 2,890 shares of NeuroPace Common Stock and a stock option for 5,368 shares. Both were granted as equity compensation and increase her direct ownership and potential future stake in the company, subject to vesting conditions tied to continued service.

What are the terms of Lisa Andrade’s new NeuroPace stock option grant?

The new stock option covers 5,368 shares of NeuroPace Common Stock at an exercise price of $15.74 per share and expires on June 4, 2036. The option vests in twelve equal monthly installments, conditioned on her continuous service through each vesting date.

How do the newly granted NeuroPace shares to Lisa Andrade vest?

The 2,890 Common Stock shares granted to Lisa Andrade vest in twelve equal consecutive monthly installments. Each installment requires her to remain in continuous service through the applicable vesting date, aligning her compensation with ongoing board service at NeuroPace.

How many NeuroPace shares does Lisa Andrade hold after these transactions?

After the reported Form 4 transactions, Lisa Andrade directly holds 2,890 shares of NeuroPace Common Stock. She also holds a stock option covering 5,368 underlying shares, which may be exercised at $15.74 per share as they vest over twelve monthly installments.

Are Lisa Andrade’s NeuroPace equity awards open-market purchases or compensation grants?

The transactions are compensation-related grants, not open-market purchases. Both the 2,890 Common Stock shares and the 5,368-share stock option were awarded to Lisa Andrade at no cash cost, subject to time-based vesting linked to her continued service with NeuroPace.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Lisa

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		2,890(1)	A	$0	2,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.74	06/05/2026		A		5,368		(2)	06/04/2036	Common Stock	5,368	$0	5,368	D

Explanation of Responses:

1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)